Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cencora, Inc. filings document material events for a NYSE-listed pharmaceutical distribution and healthcare solutions company. Recent 8-K disclosures furnish quarterly operating results, Regulation FD information, executive officer transition details, annual meeting voting results and entries into material definitive agreements.
The company’s regulatory record also covers capital-structure matters, including common stock and listed senior notes, registered public debt offerings and the terms of multiple senior note maturities. Governance filings describe director elections and other shareholder voting matters, while material-event reports connect financing activity and completed acquisitions to the company’s operating and financial disclosures.
Cencora, Inc. amended and restated its multi-currency senior unsecured revolving credit facility, increasing aggregate lender commitments to $7.0 billion from $5.5 billion and extending the maturity to July 2031. Borrowings accrue interest at margins ranging from 69.5 to 110 basis points over benchmark rates and 0 to 10 basis points over alternate base and Canadian prime rates, with covenants including a maximum financial leverage ratio and customary events of default.
The company also executed an Omnibus Amendment to its receivables securitization structure, reducing the Receivables Securitization Facility commitment from $1.5 billion to $1.0 billion while increasing the accordion feature to $1.0 billion and adding a new uncommitted purchaser. Accounts receivable originated by ABDC and ASD are sold to ARFC, which in turn sells interests to purchaser groups, with Cencora acting as performance guarantor, providing an additional liquidity and funding source for ongoing business needs.
Cencora reported strong fiscal third-quarter 2026 results, with revenue of $84.8 billion, up 5.1% year-over-year, and gross profit of $3.6 billion, up 24.1%. GAAP diluted EPS rose to $3.94 from $3.52, while adjusted diluted EPS increased to $4.48 from $4.00.
Operating income grew 29.1% to $1.1 billion, driven by higher margins in U.S. Healthcare Solutions after the February 2026 OneOncology acquisition and growth in specialty and GLP-1 products, partly offset by higher operating expenses and a 72.0% rise in net interest expense to $140.7 million. Net income attributable to Cencora was $763.5 million. For the first nine months, revenue increased 4.8% and diluted EPS reached $15.21 versus $9.70, reflecting a $1.1 billion gain on remeasurement of the prior OneOncology stake.
Outlook and capital allocation were updated: fiscal 2026 adjusted EPS guidance was raised to $17.75–$17.95; adjusted operating income is projected to grow 13–14%, revenue 4–6%, and adjusted free cash flow about $3.0 billion with approximately $900 million in capital expenditures. Cencora repurchased $1 billion of shares in the quarter and declared a $0.60 per-share dividend payable August 31, 2026.
NALLY DENNIS M reported acquisition or exercise transactions in this Form 4 filing.
Cencora, Inc. reported that director Dennis M. Nally received a grant of 113 shares of common stock on July 31, 2026 at $311.34 per share, issued in lieu of a $35,000 quarterly cash retainer under the Non-Employee Director Compensation Program. After this award, he directly holds 13,188 shares.
Cooper Ellen reported acquisition or exercise transactions in this Form 4 filing.
Cencora director Ellen Cooper received a grant of 97 restricted stock units on July 31, 2026, in lieu of a $30,000 quarterly cash retainer under the Non-Employee Director Compensation Program. The award equates to $311.34 per share, bringing her direct holdings to 893 shares, with receipt deferred until she leaves the board.
Tyler Lauren M reported acquisition or exercise transactions in this Form 4 filing.
Cencora, Inc. reported that director Lauren M Tyler received a grant of 97 restricted stock units representing common stock on 2026-07-31 at a reference price of $311.34 per share. The award was granted in lieu of a $30,000 quarterly cash retainer under the Non-Employee Director Compensation Program, with receipt of shares deferred until cessation of service. Following the grant, Tyler directly holds 4,456 shares of common stock.
Cencora, Inc. Executive Vice President Silvana Battaglia acquired 58.2040 shares of common stock on 2026-06-30 at $240.5330 per share through the company’s Employee Stock Purchase Plan, as described under Rule 16b-3(c) and 16b-3(d). Following this compensation-related acquisition, she directly holds 23,624.0120 common shares.
Cencora, Inc. Executive Vice President Elizabeth S. Campbell acquired additional common stock through the company’s Employee Stock Purchase Plan. She obtained 49.889 shares of common stock at a price of $240.533 per share in this routine, compensation-related transaction. Following the purchase, she directly holds 30,755.556 shares of Cencora common stock.
Boratto Eva C reported acquisition or exercise transactions in this Form 4 filing.
Cencora, Inc. reported that Chief Financial Officer Eva C. Boratto received a grant of 21,304 Restricted Stock Units. These RSUs were granted for no cash consideration and will vest in three equal annual installments on June 29, 2027, June 29, 2028, and June 29, 2029. Following this award, she holds 21,304 RSUs directly.
Cencora, Inc. Chief Financial Officer Eva C. Boratto filed an initial Form 3 reporting a small ownership position in the company’s common stock. She reports 1 share held directly and 2 shares held indirectly through a trust for her spouse and children, with beneficial ownership disclaimed except for any pecuniary interest.
Cencora, Inc. director Lauren M. Tyler reported an open-market purchase of 550 shares of Common Stock at $270.23 per share. After this buy, Tyler directly holds 4,359 Cencora shares, indicating a modest increase in personal ownership.